Supporting the thesis that high IL-6 baseline levels imply a poorer outcome was concluded after a Phase II clinical trial by Dorff et al. in which Siltuximab, a Monoclonal Antibody against Interleukin 6 in pre-treated patients with prostate cancer, was applied [38]. This evidence concerns the gene IL6 and prostate cancer.